Search Videos and More
Video
PRISM-AC Study Presented by Abby Rosenberg, MD, MS.
A new psychosocial intervention is showing promising results for adolescents and young adults (AYA) facing advanced cancer.
Video
Colon Cancer Study Presented by Sara Char, MD.
A new study shows that consuming an anti-inflammatory diet could extend overall survival after treatment for stage 3 colon cancer.
Video
NSCLC Study Presented by Julia Rotow, MD.
Dr. Julia Rotow presented results from a study using a cell-free DNA (cfDNA)-guided strategy to personalize first-line treatment for advanced non-small cell lung cancer.
Video
ReACT 1.0 Study Presented by Glenn Hanna, MD.
Dr. Glenn Hanna presented phase 2 data suggesting that circulating HPV DNA could serve as a real-time biomarker to guide treatment intensity in HPV-positive oropharyngeal cancer.
Video
Stereotactic Radiation Presented by Ayal Aizer, MD.
Dr. Ayal Aizer of Dana-Farber Brigham Cancer Center presents results at #ASCO25 from a phase 3 trial on stereotactic radiation.
Video
DESTINY-Breast09 Presented by Sara Tolaney, MD, MPH.
Dr. Sara Tolaney of Dana-Farber shares pivotal results from the DESTINY-Breast09 phase 3 trial.
Video
Checkmate 214 Presented by Toni Choueiri, MD.
Dr. Toni Choueiri shares groundbreaking 9-year results from the CHECKMATE-214 trial.
Document
Treatment Guideline: Datopotamab Deruxtecan (Dato-DXd) in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer
Our Breast Oncology Center held multidisciplinary meetings to discuss recommendations regarding the use of datopotamab deruxtecan (Dato-DXd) in patients with hormone receptor-positive/HER2-negative metastatic breast cancer.
News
T-DXd Plus Pertuzumab Outperforms Standard of Care for First-Line Treatment of Advanced HER2-Positive Breast Cancer
In an interim analysis from the DESTINY-Breast09 study, the combination of the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) plus pertuzumab, nearly doubled progression-free survival compared to the currently accepted standard treatment with taxane chemotherapy plus trastuzumab and pertuzumab (THP) for first-line therapy of metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
News
Dana-Farber Research News 06.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from May 1 through May 15.
News
Diet Influences Survival After Stage III Colon Cancer, Dana-Farber Study Finds
A Dana-Farber study shows that an anti-inflammatory diet could extend overall survival after treatment for stage III colon cancer.
News
Adding Immune Checkpoint Inhibitor to Standard Chemotherapy Regimen Improves Outcomes in Stage 3 Colon Cancer, Study Finds
Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon cancer that is deficient in DNA mismatch repair (dMMR), Dana-Farber Cancer Institute investigator Dr. Jeffrey Meyerhardt and his colleagues report at the 2025 American Society of Clinical Oncology (ASCO) meeting.